ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO175

Heart of Stone: Cardiogenic Shock from Myocardial and Mitral Valve Calcification with Systolic Anterior Motion (SAM) Defect after Valve Replacement in a Patient on Chronic Hemodialysis (CHD)

Session Information

  • CKD-MBD: Clinical
    October 24, 2024 | Location: Exhibit Hall, Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Bone and Mineral Metabolism

  • 502 Bone and Mineral Metabolism: Clinical

Authors

  • Verma, Ashish, Baystate Medical Center, Springfield, Massachusetts, United States
  • Braden, Gregory Lee, Baystate Medical Center, Springfield, Massachusetts, United States
  • Greco, Barbara A., Baystate Medical Center, Springfield, Massachusetts, United States
  • Hodgins, Spencer, Baystate Medical Center, Springfield, Massachusetts, United States
Introduction

Myocardial & valve calcification has been descibed in CHD autopsy studies but has rarely been reported to be a clinical cause for CHF in CHD pts. We describe a pt who after 16 years of dialysis developed severe dyspnea & mitral stenosis from annular calcification(C) She had HFpEF & later developed cardiogenic shock & SAM after mitral replacement with severe LV outflow track obstruction. Autopsy showed severe myocardial C & 50 % myocaridal fibrosis, a new cause of clinical HFpEF in CHD pts.

Case Description

A CHD pt with years of PTH > 2000 pg/ml, hypercalcemia and CaPhosphorous(P) product 54-123 developed dyspena with mitral stenois with a 16 mmHg gradient. She was on CHD from 1988-90 & then 1992 -2006. After PTH removal in 1997 she had severe hypocalcmia ,PTH < 1.0 pg/ml, & she got over 2000 mcg of iv calcitriol & 11,100 grams of CaP binders from 1992 to 2006. Cardiac studies showed a small heart with a cardiothoracic ratio of .36, LVEF 70 %, severe mitral gradient of 14-16 mmHg, LVH, & pulmonary artery presssure of 79 mmHg & mild tricuspid regurg. The coronary arteries had minimal changes. At surgery severe mitral annular calcification allowed only a pediatric St.Jude's valve. On day 3 she devleoped shock requiring fluids & 3 pressors. TEE showed marked SAM with severe obstruction of the LV ouflow track, severe pulmonay hypertension & severe tricuspid regurg & RV failure. LVEF was 65%. At death autopsy showed a small heart size despite a weight of 600 gms.with diffuse myocardial C on H&E & 50 % of the myocadium had fibrosis on trichrome stains. Calcium deposits were minimal in the coronary arteries.

Discussion

We conclude: 1) Diffuse myocardial C & fibrosis can occur in CHD pts from parathyroid & CaP dysrgulation & over use of calcium based P binders and IV Calcitriol. 2) Myocardial calcium causing severe fibrosis is a rare but important cause of dyspnea & HFpEF with a small heart in CHD pts. 3) SAM of the mitral valve has never been reported in CHD pts & can occur after mitral valve replacement 4) Prexisting tricuspid regurg & pulmonary hypertension are risk factors for severe RV failure after mitral valve replacement. 5) Simultaneous tricuspid valve replacement or repair may be needed in such pts receivng a mitral valve prosthesis.